An observational study on drug interactions caused by proton pump inhibitors

Abstract

Proton pump inhibitors (PPIs) are widely used to treat gastric acid-related diseases worldwide and in our country. The high reliability of PPIs also allows long-term use for appropriate indications in chronic diseases, which increases the possibility of drug-drug interactions. Therefore, it is clear that the usage of PPIs should be monitored in terms of drug-drug interactions to provide drug treatment success and patient safety. The ability of pharmacists, the closest health consultants, to identify these interactions during prescription fulfillment will significantly contribute to treatment success. Although many studies deal with the rational use of PPIs and drug interactions, the number of studies revealing observational drug interactions is minimal. This research aims to determine drug-drug interactions frequently encountered in community pharmacies for PPIs, which interact with many drug groups and are commonly prescribed. For this purpose, approximately 1700 prescriptions supplied by a selected community pharmacy, serving in Van, were examined. One hundred sixty-four of the prescriptions were evaluated by considering the study’s limitations. Drug-drug interactions were checked by three different electronic database. It was determined that 73 of 164 prescriptions had interactions in at least one of the three databases. In 73 prescriptions, 86 drug interactions were observed. 34% of the interactions detected in the study were caused by lansoprazole.

Keywords

• Comunity Pharmacy
• Drug Interaction
• Proton Pomp Inhibitors

References

1. Erden MÇ, Pamuk G. Erden B, Koç, EM. Bir Eğitim Aile Sağlığı Merkezine Başvuran ve Herhangi Bir Nedenle Proton Pompa İnhibitörü Kullanan Hastaların Tedavi Farkındalık Düzeyi. Forbes J Med. (2021);2(3):166-70. https://doi.org/10.4274/forbes.galenos.2021.41736
2. Boardman HF, Heeley G. The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors. International journal of clinical pharmacy. (2015);37(5):709-16. https://doi.org/10.1007/s11096-015-0150-z
3. Okutan E. İç Hastalıkları Servislerinde Yatan Hastalarda Uygun Olmayan Endikasyonlarda Oral Proton Pompası İnhibitörleri Kullanımının Tespit Edilmesi ve Hasta Uyuncunun Değerlendirilmesi [Yüksek Lisans Tezi]. Ankara: Hacettepe Üniversitesi; (2017).
4. Johnson DA, Katz PO, Armstrong D, et al. The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and Delphi consensus. Drugs. (2017);77(5):547-61. https://doi.org/10.1007/s40265-017-0712-6.
5. Öncü Ş, Gelal A, Aslan Ö, Reyhan UÇKU. Bir üniversite hastanesinde yatan, digoksin ile tedavi edilen hastalarda omeprazol kullanımı: 2011-2015 yılları arasındaki veri analizi. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi. (2018);32(1):1-8.
6. Arı H, Muratdağı G, İnci MB, et al. Sakarya’daki Aile Hekimliği Uygulamalarından Elde Edilen Proton Pompa İnhibitörleri Reçete Verilerinin Retrospektif Olarak Değerlendirilmesi. Journal of Human Rhythm. (2020);6(3):138-46.
7. Özdemir B, Ön KB, Altıner E. Uşak Eğitim Ve Araştirma Hastanesi’ne Başvuran Hastalarda Proton Pompa İnhibitörü Kullanim Yayginliğinin İncelenmesi. Ege Tıp Bilimleri Dergisi. (2022);5(1):11-5. https://doi.org/10.33713/egetbd.1070299
8. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug safety. (2014);37(4): 201-11.

9. Andersson T, Hassan-Alin M, Hasselgren Gi Röhss, K. (2001). Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clinical pharmacokinetics, (2001);40(7):523-37. https://doi.org/10.2165/00003088-200140070-00004
10. Labenz J, Gyenes E, Peitz U, Börsch G. Ciprofloxacin-omeprazole combination therapy for eradication of Helicobacter pylori. Zeitschrift Fur Gastroenterologie, (1991);29(4):143-45.
11. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm. World Sci. (2008);30:367–74. https://doi.org/10.1007/s11096-008-9191-x
12. Roblek T, Vaupotic T, Mrhar A, Lainscak M. Drug-drug interaction software in clinical practice: A systematic review. Eur. J. Clin. Pharmacol. (2015);71:131–42. https://doi.org/10.1007/s00228-014-1786-7
13. Muhič N, Mrhar A. Brvar M. Comparative analysis of three drug–drug interaction screening systems against probable clinically relevant drug–drug interactions: a prospective cohort study. Eur. J. Clin. Pharmacol. (2017);73, 875–82. https://doi.org/10.1007/s00228-017-2232-4
14. Bilgener E. Türkiye’de 2006-2011 Yıllarında Proton Pompası İnhibitörleri Tüketiminin Bütçeye Etkisi. Journal of Faculty of Pharmacy of Ankara University. (2018);42(2):23-31. https://doi.org/10.1501/Eczfak_0000000604